HIV prevention and transmission

FTC exposure higher in young transgender men than cisgender controls

Levels of long-acting anti-HIV bNAb high in infants after 1 or 2 doses – but not high enough

BASHH 2020 PEP guidelines: online for comment

EMA supports use of dapivirine vaginal ring to prevent HIV in high-incidence countries

Long-acting cabotegravir injections are effective as HIV PrEP in gay men and transgender women: results from HPTN 083

UK government cuts HIV PrEP budget in England by a third

Cabotegravir long-acting injections prevent HIV as PrEP

PrEP recommended by NHS England (at last)

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally

No HIV transmission among Swiss infants born to mothers with undetectable viral load and who did not receive neonatal PEP

HIV in the UK – 2019 reports and data

Large phase 3 HIV vaccine study in south Africa is stopped early due to lack of efficacy

i-Base guide to HIV testing and sexual transmission (January 2020)

UK Guide to PrEP – November 2019

US government claims patent infringement by Gilead Sciences over use of F/TAF and FTC/TDF as PrEP

PrEP linked to lower HIV incidence in US, independent of TasP

US approves F/TAF for PrEP (Descovy): indication excludes risk from receptive vaginal sex

WHO update PrEP guidelines to include event-based dosing

UK issue joint guidelines on HIV discrimination in tattoo and beauty salons

PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study

Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year

Two pints of lager and a packet of PrEP please: London price for HIV PrEP drops to £17.50

Activists challenge block to generic PrEP and current US price of TDF/FTC

Fifty new HIV diagnoses at Dean Street linked to caps on IMPACT study

PARTNER 2 study published in the Lancet: global news coverage that ART stops HIV transmission

BHIVA preconference: U=U and HIV and immigration detention

bNAb research at CROI 2019: vaccine, prevention, treatment and cure…

New option for PrEP – TAF/FTC is non-inferior to TDF/FTC: results of phase 3 DISCOVER study

Arabic translation of U=U factsheet

NHS England doubles places on IMPACT PrEP study to 26,000

US CDC updates HIV rates in transgender people

UK annual HIV surveillance data published – full reports

Michigan State updates HIV disclosure laws to reflect impact of effective ART

3rd HIV Research for Prevention Conference (R4P2018) – second reports

3D printing technology has potential to individualise production of vaginal rings

3rd HIV Research for Prevention Conference (R4P2018)

How to evaluate PrEP and vaccines: urgency for next generation compounds

3D imaging show HIV infection might establish within hours

bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges

New UK PrEP guidelines 2018

UK PrEP guidelines now online (2018)

HIV diagnoses in UK drop for third year: among all ages, risk groups, and ethnicities and across most UK regions

English court finds in favour of access to generic TDF/FTC

High rates of anal HPV infection in gay men using PrEP in IPERGAY: the role of vaccination

Janssen HIV vaccine: update from APPROACH and largescale efficacy study

Resolving a diagnosis for people with persistently indeterminate HIV test results

Zero HIV transmissions in PARTNER 2 study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV

Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen

Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians

Why U=U does not apply to breastfeeding

New FDA guidance for developing PrEP drugs

UK PrEP IMPACT trial announces 3000 new places for gay men but low uptake by women, African and transgender people

Broad PrEP access in Australia reduces HIV infections even with reduced condom use by people not on PrEP

Webcasts on PrEP and women

Low PEP and PrEP awareness among trans people in London and their partners

Low awareness of PrEP in BME communities in Leeds but high interest in use

Zero or negligible risks of HIV, HBV or HCV transmission by biting or spitting

Almost 1 in 8 people with symptoms turned away from sexual health clinics in SE London: 40% are under 25 and 6% under 18 years old

Rapid PrEP uptake in Scotland exceeds expectations

PrEP engagement workshops

Update on PrEP IMPACT study (March 2018)

PrEP at CROI 2018 (part 1): Access in Australia and the US

PrEP at CROI 2018 (part 2): Animal studies for future drugs

London clinic to prescribe generic PrEP privately at £55 for 30 tablets

Post navigation